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I.

Introduction
In 2012, the imaginings of science fiction came true when scientists revealed that newly-

developed technology could enable highly-specified genetic manipulation.1 This technology,
largely known as CRISPR,2 revolutionized the field of genetics by making gene editing “faster,
cheaper, more accurate, and more efficient than other existing genome editing methods.”3 As a
result, the medical field is increasingly turning to gene editing as a potential treatment option for
innumerable conditions with a genetic basis. Scientists are rapidly pursuing clinical applications,
and it is time for leaders, legislators, and regulators to carefully examine the potential impacts of
this technology on vulnerable members of society. The law as it currently stands provides
insufficient protection from the potential harm posed by unwelcome applications of gene editing
technology. This Comment will provide an overview of current laws related to CRISPR
technology and suggest possible solutions for the regulation of its more immediate applications.
A. Technology Overview
The field of molecular genetics is a relatively new area of study, as researchers only began
to explore genome mechanics within the past century.4 Beginning in the late 1970’s, scientists
sought to understand how genes in living cells could be manipulated, leading to the development
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of several techniques to add or remove genetic sequences from strands of DNA.5 While the field
saw massive advances throughout the latter half of the 20th century (due in part to the Human
Genome Project),6 progress stalled in 1999 after clinical trial patient Jesse Gelsinger died from an
intense inflammatory reaction to a single gene therapy injection.7 This tragedy revealed a number
of problems with the oversight mechanisms and reporting requirements that regulate the field of
genetic human subject research.8 Since Jesse’s death, geneticists and regulators alike have sought
to improve the field as a whole, yet biomedical technology continues to far outpace policy and
regulation.9 The discovery of CRISPR once again presents the challenge of tempering scientific
promise with an abundance of rightful caution.
CRISPR, an acronym for “clustered regularly interspaced short palindromic repeats”
(indicating the DNA sequences that make CRISPR possible), provides scientists with a method to
“add[], remove[], or alter[ genetic material] at particular locations in the genome”.10

The

technology allows for much more targeted gene editing than previous methods because:
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[w]ith CRISPR, researchers create a short RNA template that matches a target DNA
sequence in the genome. . . Strands of RNA and DNA can bind to each other when
they have matching sequences. The RNA portion of the CRISPR, called a guide
RNA, directs Cas9 [CRISPR-associated protein 9] enzyme to the targeted DNA
sequence. Cas9 cuts the genome at this location to make the edit. CRISPR can make
deletions in the genome and/or be engineered to insert new DNA sequences.11
This represents a vast improvement in the reliability of gene editing. Where prior methods were
resource intensive and technically complex, requiring synthesis of new proteins for each desired
change, CRISPR represents a much more simplified (and cheaper) means of achieving a more
precise result.12 Whereas older technologies saw, at best, a ten percent success rate,13 CRISPR
may provide up to six times the efficiency of these methods “at a small fraction of time and
price.”14
As a result of the tremendous promise that CRISPR holds, “CRISPR-Cas genome editing
tools have been adopted rapidly in the research community[ and] . . . are quickly finding
applications in the commercial sector.”15 These potential applications of CRISPR are innumerable
and may impact human life positively or negatively, both inside and outside the medical field.16
While the desire to cure insidious genetic diseases is certainly a noble goal, CRISPR technology
also raises a wide variety of ethical issues that scientists must take into account.17 These concerns
go beyond germ-line editing (editing of genes that can be passed on to future generations) and
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include applications of gene editing to somatic cells (where edits would not be passed to future
generations).18
B. The Somatic/Germ-Line Ethical Divide
An additional aspect of the underlying science—whether manipulated genes could be
passed on to future generations—complicates the implications of CRISPR technology. This
complication arises from the fact that living organisms are composed of two primary cell types.
Somatic cells, which make up the vast majority of cells in the human body, do not pass their genes
on to future generations.19 “A somatic cell is any cell of the body except sperm and egg cells.
Somatic cells are diploid, meaning that they contain two sets of chromosomes, one inherited from
each parent. Mutations in somatic cells can affect the individual, but they are not passed on to the
offspring.”20 Germ-line cells, on the other hand, develop gametes (or sperm and eggs) and do pass
genetic information, including CRISPR modifications, to future generations.21 This ability (or
inability) to pass genetic information to future progeny has become the foundation of the present
CRISPR bioethics debate.
With the somatic/germ-line distinction forming the dividing line in CRISPR bioethics,
many bioethics leaders assert that research on somatic application should forge ahead, while a
voluntary moratorium should be placed on germline editing.22 Although nice in theory, the
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obvious weaknesses in this approach are readily apparent. Due in part to the non-binding nature
of the voluntary moratorium, germ-line use of CRISPR has already been used to manipulate fetal
DNA.23 In 2018, Professor He Jiankui created the first “CRISPR babies” in China,24 a project he
undertook independent of his academic laboratory.25

Ultimately, there was significant

international backlash against Professor He’s experiment, and in December 2019, the Chinese
government sentenced him to three years in prison.26 While the Chinese government may be
seeking to quell international ethics concerns, criminalization of scientific research will have a
dangerous chilling effect on scientists performing necessary and beneficial work.27 The United
States is not immune to germ-line experiments, and it is short-sighted to think that social pressure
will control the expansion of ethically challenging applications of CRISPR in American
institutions.28 Researchers in the United States are currently working to apply CRISPR techniques
to human sperm29 and may rely on funding sources that evade typical regulatory schemes.30 Such

23
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female infertility regardless of the underlying cause.” Palermo Foundation, Our Mission (last visited Feb. 14, 2020),
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germ-line edits would inevitably be passed on to future generations,31 fundamentally altering their
development. A middle ground between criminalization and mere social pressure would be helpful
in controlling the expansion of these efforts before they go too far.
There is no doubt that the prospect of CRISPR application in a clinical setting has caused
significant alarm in both scientific and lay communities; however, this alarm has largely been
narrowed to the germline context, leading to a failure to consider negative consequences of somatic
application.32 As a result, somatic research regarding CRISPR applications are more likely to
progress without much questioning. Professor He’s ability to create CRISPR edited babies reveals
just how simple and efficient genetic manipulation has become.33 In the United States, clinical
research on somatic cells currently includes trials for various relapsed cancers, sickle cell anemia,
non-Hodgkins lymphoma, and inherited blindness.34 More fundamental and pre-clinical research
is also occurring, and likely to progress quickly.35 The scientific community is rapidly moving
towards application of CRISPR across a variety of biomedical areas.36 In light of this revolutionary
shift, somatic applications cannot be ignored.
The ethical and legal debate cannot stop with germ-line concerns, and it must not be left
solely to the scientific community. While germ-line applications are undoubtedly alarming,
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MOL. GENETICS R79 (2018).
36
Patrick D. Hsu, et al., Development and Applications of CRISPR-Cas9 for Genome Engineering, 157 CELL 6
(2014) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4343198/.

6

widespread somatic uses are much closer in time and present their own ethical complexities. Thus,
this comment will seek to demonstrate the potential implications of somatic editing by examining
its application in the field of psychiatry and assessing the ability of mental disability law to address
the negative consequences of such applications.
applications of CRISPR in psychiatry.

Section II will outline possible somatic

Then, Section III will examine the constitutional

protections of the bodily autonomy of mentally ill persons and explore the current state of mental
disability law regarding bodily autonomy. Finally, Sections IV and V will look to present
regulatory structures to determine whether they are capable of addressing somatic CRISPR uses
and consider potential solutions for leaders to adopt moving forward.
II.

Potential for Gene Editing to be Exploited in Psychiatry

A. In Pursuit of Neurobiological Clarity
Psychiatry is a particularly pertinent area for CRISPR research for several reasons. First,
recent psychiatric research has failed to produce new, effective medications.37 Drug development
has stalled as new medication targets for psychiatric purposes have not been identified in quite
some time.38 The most commonly prescribed psychiatric drugs were approved by the FDA more
than 30 years ago,39 and drugs for diseases such as schizophrenia merely subdue a singular
symptom of the disease, rather than treating its underlying cause.40 As a result of this relative
standstill, researchers are seeking out new avenues for potential treatment.41 CRISPR is not only
being explored as a way to cure or eliminate mental illness, but it is also being looked at, more

37

Why
Study
the
Genetics
of
Psychiatric
Disorders?,
BROAD
INSTITUTE,
https://www.broadinstitute.org/files/news/media-kit/WhyStudyGenetics.pdf
38
Id.
39
Jim Dryden-Wustl, CRISPR Powers the Hunt for New, Better Antidepressants, FUTURITY (August 17, 2018),
https://www.futurity.org/antidepressants-crispr-1841722/.
40
Research Highlight: Schizophrenia, BROAD INSTITUTE (2016), https://www.broadinstitute.org/research-highlightsschizophrenia.
41
Dryden-Wustl, supra note 39.
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immediately, to increase the effectiveness of psychiatric medications.42 Since this research has, at
a minimum, aided scientific understanding of mental illness, it will likely forge ahead in years to
come.43
In addition to the drug development stalemate, psychiatry is a prime area for somatic
applications of CRISPR due to the highly heritable nature of psychiatric disease.44 Research into
the etiology of mental illness shows that genetics, in addition to environmental factors, play a
significant role in the development of mental illness.45 In fact, some of the most debilitating mental
illnesses are also thought to have the strongest genetic markers,46 and research continues to
“indicate[] widespread genetic overlap across different types of psychiatric disorders, particularly
between attention-deficit/hyperactivity disorder (ADHD), bipolar disorder, major depressive
disorder, and schizophrenia.”47 As a result of these strong genetic links, scientists are beginning
to explore the possibility of gene editing as a potential treatment avenue for psychiatric illnesses.48
Ultimately, the impact these diseases have on patients’ lives, combined with the fact that they are
often difficult to treat, will continue to make them prime targets for CRISPR research and

42

Id. See also Stanley Center Therapeutics Projects, BROAD INSTITUTE: Stanley Center for Psychiatric Research,
https://www.broadinstitute.org/therapeutics/stanley-center-therapeutics-projects.
43
See, e.g., Stanley Center Therapeutics Projects, BROAD INSTITUTE: Stanley Center for Psychiatric Research,
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45
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NEUROPSYCHOPHARMACOLOGY REVIEWS 223 (2018).
46
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Zwicker, Etiology in Psychiatry: Embracing the Reality of Poly-Gene-Environmental Causation of Mental Illness, 16
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48
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2016), http://sitn.hms.harvard.edu/flash/2016/crispr-in-neuroscience-how-precision-gene-editing-may-unravel-howthe-brain-works-and-why-it-sometimes-doesnt/; Fighting Depression with CRISPR, Synthego: The Bench (August
23, 2018), https://www.synthego.com/blog/crispr-depression; S.K. Powell, J. Gregory, S. Akbarian & K.J. Brennand,
Application of CRISPR/Cas9 to the Study of Brain Development and Neuropsychiatric Disease, 82 MOL. CELL
NEUROSCI. 157 (2017).
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application in the clinical setting. At present, at least two major U.S. institutions have dedicated
substantial projects to exploring genetically-based treatments of mental illness.49 The Stanley
Center for Psychiatric Research of the Broad Center of MIT and Harvard, based in Cambridge,
Massachusetts, is focused on exploring the etiology of schizophrenia and other mental illnesses,
identifying biomarkers of psychiatric disease, and “above all, [developing] new treatments.”50
Meanwhile, the University of California at Los Angeles has launched a “Grand Challenge” focused
on Depression, and the Center for Neurobehavioral Genetics will focus its efforts on developing
new genetically-based treatments for the illness.51 Ironically referring to the Grand Challenge as
the “Manhattan Project for depression,” UCLA researchers intend to make a tremendous impact,52
and there is no doubt that the development of CRISPR technology will help them, and others53,
move quickly towards their goals.54
B. Pumping the Brakes on Psychiatric Genetics
i.

Substantive Concerns
While it clearly makes sense to explore the genetic underpinnings of mental illness, there

are also a number of reasons why advancement in this area via the application of CRISPR

49

See, e.g., Stanley Center, BROAD INSTITUTE, infra note 50, and UCLA Grand Challenges, infra note 51.
Stanley Center, BROAD INSTITUTE: Stanley Center for Psychiatric Research, https://www.broadinstitute.org/stanley.
51
See Depression, UCLA GRAND CHALLENGES, https://grandchallenges.ucla.edu/depression/.
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2019), https://www.discovermagazine.com/mind/can-we-eliminate-depression-a-massive-new-project-aims-to-dojust-that.
53
The Virginia Institute for Psychiatruc and Behavioral Genetics at the Virginia Commonwealth University seeks to
study the genetic etiology of psychiatric illness as well; however, the VCU Institute is pursuing more general
understandings through foundational research, as opposed to the solution-driven focus of the Broad Institute and
UCLA’s Grand Challenge. See Virginia Institute for Psychiatric and Behavioral Genetics, Mission Statement (last
visited Feb. 14, 2020), https://vipbg.vcu.edu/about/mission-statement/.
54
Interestingly, two of the leaders of the UCLA project identified the first genetic markers of depression by studying
Chinese women. See id.; Roseann E. Peterson, et al, The Genetic Architecture of Major Depression in Han Chinese
Women, 74 J. AM. MED. ASS’N PSYCHIATRY 162 (2017). China’s protection of its citizen’s genetic information and
privacy is questionable at best. See, e.g., Emma Yasinski, China Clamps Down on Foreign Use of Chinese Genetic
Material and Data, THE SCIENTIST (June 17, 2019), https://www.the-scientist.com/news-opinion/china-clamps-downon-foreign-use-of-chinese-genetic-material-and-data-66016; Sui-Lee Wee, China Uses DNA to Track Its People, With
the Help of American Expertise, NY TIMES (Feb. 21, 2019), https://www.nytimes.com/2019/02/21/business/chinaxinjiang-uighur-dna-thermo-fisher.html.
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technology must be approached with extreme caution. Although mental illness is highly heritable,
scientists suspect that these illnesses are also polygenic, meaning that multiple genes contribute to
their pathogenicity. In addition, the role of epigenetics (changes to the DNA that do not affect the
sequences themselves but can influence gene expression nonetheless) in the development of
psychiatric illnesses is not fully understood.55 Both of these aspects of the underlying science can
apply to diseases that are non-psychiatric in nature, and somatic editing for those illnesses my
present similar challenges. These challenges are not only technological, but also presents ethical
in nature. For example, primary candidates for initial, experimental uses of psychiatric (and nonpsychiatric) somatic gene-editing will be those patients afflicted with the most serious conditions,
experiencing the most severe symptoms and facing the greatest amount of treatment resistance via
conventional treatment methods.56 As these patients are likely desperate for new treatments for
their illnesses, researchers must have an awareness of the impact such desperation can have on
patients’ decision-making.57
In addition to the technological issues presented, polygenicity may pose other concerns as
well. The impact that changing only one or two genes contributing to an illness, as opposed to all
of the genes known to be associated, could have unimaginable and unpredictable consequences.58
Furthermore, the very nature of what CRISPR technology would seek to do, i.e., “erase” or
“replace” characteristics at the very core of a person, warrants serious concern and questioning
about its role in psychiatric treatment and medical care more generally. This concern about

55

What is epigenetics?, National Institutes of Health: Genetics Home Reference,
https://ghr.nlm.nih.gov/primer/howgeneswork/epigenome.
56
Alexandra L. Foulkes, Takahiro Soda, Martilias Farrell, Paola Giusti-Rodriguez & Gabriel Lazaro-Munoz, Legal
and Ethical Implications of CRISPR Applications in Psychiatry, 97 N.C.L. REV. 1359, 1383-86 (2019),
https://docs.wixstatic.com/ugd/ba77b5_5d2805bbecea47dbb70ec3eda4fdc199.pdf.
57
Id.
58
Carolyn Brokowski & Mazhar Adli, CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool,
431 J. MOL. BIOL. 88, 90 (2019).
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“erasing “ characteristics also applies to non-psychiatric diseases, as the manipulation of “bad
genes” to “good genes” will undoubtedly reduce diversity, neural and otherwise.59, 60 Clinicians
must engage with patients in a careful risk-benefit analysis that takes into account the individual
needs of the patient and seeks to ensure that “the risks and burdens that accompany the intervention
[are not] greater than the baseline state of the individual.”61 They must also carefully consider the
biological and sociological implications that an inevitable reduction in diversity might have.62
ii.

Procedural Concerns
Psychiatric research on human patients also involves substantial concerns regarding

informed consent and voluntary participation.63 Care must be used in the informed consent
protocol of any experimental application of new technology; however, the nature of mental illness
is such that eligible patients are at a heightened risk of being taken advantage of and manipulated
during the medical decision-making process.64 Even the Supreme Court, in Zinermon v. Burch,
has recognized the inherent concerns regarding the ability of mentally ill patients to provide
legitimate informed consent regarding their medical treatment:
The risk is that some persons who come into [the state’s] mental health facilities
will apparently be willing to sign forms authorizing admission and treatment, but
will be incompetent to give the “express and informed consent” required for
voluntary placement under [the statute]. Indeed, the very nature of mental illness
makes it foreseeable that a person needing mental health care will be unable to
understand any proffered “explanation and disclosure of the subject matter” of the
forms that person is asked to sign, and will be unable “to make a knowing and
willful decision” whether to consent to admission. A person who is willing to sign
forms but is incapable of making an informed decision is, by the same token,
59

FRANCOISE BAYLIS, ALTERED INHERITANCE: CRISPR AND THE ETHICS OF HUMAN GENOME EDITING 19-35 (2019).
For a discussions of neurodiversity, see John Elder Robison, What is Neurodiversity?, PSYCHOLOGY TODAY (Oct.
7, 2013), https://www.psychologytoday.com/us/blog/my-life-aspergers/201310/what-is-neurodiversity, and Robert
D. Austin & Gary P. Pisano, Neurodiversity as a Competitive Advantage, HARVARD BUSINESS REVIEW (June 2017,
99-103), https://hbr.org/2017/05/neurodiversity-as-a-competitive-advantage.
61
Laura Weiss Roberts & Shaili Jain, Ethical Issues in Pharmacology, 28 PSYCHIATRIC TIMES (May 7, 2011),
https://www.psychiatrictimes.com/bipolar-disorder/ethical-issues-psychopharmacology.
62
BAYLIS, ALTERED INHERITANCE, supra note 59.
63
John S. Carroll, Consent to Mental Health Treatment: A Theoretical Analysis of Coercion, Freedom, and Control,
9 BEHAVIORAL SCI. & L. 129 (1991).
64
Id.
60
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unlikely to benefit from the voluntary patient’s statutory right to request discharge.
. . . Such a person thus is in danger of being confined indefinitely without benefit
of the procedural safeguards of the involuntary placement process, a process
specifically designed to protect persons incapable of looking after their own
interests.”65
Thus, the increased vulnerability of the mentally ill can make it difficult to determine whether
consent without coercion has truly been given.66 These concerns are likely present with other
vulnerable populations as well, such as minors or developmentally delayed individuals.
Furthermore, the stigma surrounding mental illness is of particular concern for psychiatric patients,
as this stigma has the potential to lead to force, manipulation, or inappropriate persuasion from
medical professionals and family members, whether these individuals are aware of their impact or
not.67

Shame and emotional pain associated with psychiatric disease may encourage an

individual’s loved ones to assert significant pressure to accept treatment, leading to consent that is
not truly voluntary and autonomous.68
In addition to the concerns surrounding informed consent, use of CRISPR in the psychiatric
context also warrants serious consideration regarding patient privacy. Whether CRISPR is used
to directly modify a patient’s DNA or derivatives of the technology are used to identify better
pharmacological treatment options, application of CRISPR in the clinical psychiatric context will
“likely require collecting participant’s genetic information.”69 Genetic privacy is not the only
concern here—privacy of mental health records is also of extreme importance, especially due to
the widespread stigma about psychiatric diagnoses that persists in society.70 Since genetic
information will be directly tied to data about a patient’s mental health status, “clinicians and

65

Zinermon v. Burch, 494 U.S. 113, 133 (1990).
John S. Carroll, supra note 63.
67
Id. at 130.
68
Id. at 131.
69
Foulkes, et al., supra note 56, at 1388–89.
70
Id.
66
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researchers should take particular care to protect this population from improper disclosure and
misuse of medical information.”71
III.

Constitutional Authority on the Bodily Autonomy of the Mentally Ill
Most Americans would recognize that bodily autonomy is a fundamental right possessed

by all persons and that this right is treated with such high regard in our legal system that little can
overcome it. These ideas are supported by the longstanding “recogni[tion] of the common law
right against bodily intrusions,”72 evidenced “in the torts of battery and trespass.”73 Despite the
fact that bodily autonomy “is considered among the most cherished of rights,”74 the Supreme
Court’s treatment of the bodily autonomy of vulnerable groups, such as the mentally ill,
complicates this view75—“[f]ailure to appreciate the true invasiveness of many bodily intrusions
has made the Court exceedingly deferential to state authority and ‘professional judgment’ in
deciding when intrusions are necessary.”76 Ultimately, the jurisprudence of our nation’s highest
Court reveals that respect for individual bodily autonomy is substantially undermined by the
Court’s treatment of persons traditionally seen as “biologically inferior”. This Section will
examine jurisprudence regarding the mentally ill; however, the notion of “biological inferiority”
extends beyond this context and has been evidenced in both our nation’s and the world’s history.77
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A. Forced Sterilization
The starkest example of disrespect for the bodily autonomy of “biologically inferior”
mentally ill persons can be seen in the Court’s infamous opinion in Buck v. Bell. In Buck, the
Court upheld the constitutionality of forced sterilization for “feeble-minded imbeciles” that were
being held in state-run institutions.78 Carrie Buck, a supposedly mentally ill woman,79 had been
committed to the state mental institution “in due form,”80 language intended to suggest that her
due process rights had not been violated. Buck’s mother was also mentally ill, and Buck, herself,
was the mother of a mentally ill child.81 As a result of her “feeble-minded” lineage, Ms. Buck was
subjected to a surgical sterilization procedure at the discretion of the institution’s superintendent.82
She was just eighteen years old at the time.83 In upholding the constitutionality of the procedure
against a Fourteenth Amendment challenge, Justice Holmes stated: “[i]t is better for all the world,
if . . . society can prevent those who are manifestly unfit from continuing their kind.”84
Though Buck v. Bell is an old case, it has never been directly overturned by the Court85,
and the Court has explicitly declined the opportunity to do so.86 The case has been dismissed as a
product of its time, with modern courts admitting that its language is incendiary87; however, the
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validity of this idea is, at best, questionable, since forced sterilization was a contentious issue even
in 1927 when the case was decided.88 Despite the repudiation that has occurred, its continuance
as a case that has merely been questioned, rather than overturned, leaves the door open for highly
invasive, government-imposed procedures to be held constitutional. Ultimately, “Buck [continues
to] represent[] a milestone in the affirmation of governmental power over individual rights, but
more specifically, Buck is a landmark in the endorsement of intrusive medical procedures as tools
to be used for state ends.”89 Its continued presence in the Supreme Court’s jurisprudence poses a
dangerous precedential threat in our present genetic age.
B. Forced Medication
While Mills v. Rogers is less obviously problematic than Buck v. Bell, the case still serves
to undermine the rights of mentally ill persons within the American justice system. Mills v. Rogers
involved coerced administration of medication to a mentally ill patient, and the parties involved
decided to stipulate at trial that a liberty interest in avoiding such administration of psychoactive
drugs exists.90 This stipulation ultimately enabled the Supreme Court to avoid determining
whether such an interest is protected by the Constitution.91 In assuming the stipulation, the Court
leaves room for an argument against a Constitutional right against this sort of bodily intrusion,
weakening the protection the Constitution provides to psychiatric patients. Furthermore, the Court
uses a circular argument to avoid saying anything substantive on the matter. Relying on the
stipulated assumption that a liberty interest in avoiding forced medication exists, the Court asserts
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that state law could only increase any interest that may exist, yet still fails to provide any guidance
regarding how these interests are to be assessed or balanced against state interests.92
By essentially punting on whether individuals actually do have a liberty interest in avoiding
forced medication, the Supreme Court left the question open for lower courts to decide in a
scattered and hesitant manner.93 In asserting that federal constitutional requirements for due
process do not control and leaving such process concerns to states to decide, the Court underlined
its refusal to apply strict scrutiny in cases concerning government intrusions of bodily autonomy,94
and left open a black hole in which the Eleventh Amendment could be asserted by states against
the rights of the individual.95 After a slew of litigation between state and federal courts, the Rogers
litigation ultimately ended with the First Circuit deciding that state level protections were
sufficient.96
C. Involuntary Commitment
The Supreme Court’s lack of respect for the bodily autonomy of the mentally ill can even
be seen in its jurisprudence around involuntary civil commitment. In Addington v. Texas, the
constitutionality of indefinite civil commitment to a mental hospital was challenged.97 Frank
Addington was sentenced to involuntary commitment for an indefinite period of time following a
conviction of “assault by threat” on the basis of a “clear and convincing evidence” standard.98
Addington appealed, arguing that the jury should have been instructed on the basis of a “beyond a
reasonable doubt” standard.99 Ultimately, despite the fact that such involuntary commitment
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would have the same impact on Addington’s bodily autonomy as a prison sentence, the Supreme
Court upheld the use of the lesser evidentiary standard, stating that it did not violate due process
when used for civil confinement purposes.100
The Addington opinion also suggests that substantial deference should be given to
psychiatric professionals for purposes of the balancing test required in the civil commitment
context.101 Since the courts must balance both the interests of the individual (in not being confined)
and the interests of the state (under its parens patriae powers),102 the “beyond a reasonable doubt”
standard is too high a burden for a juror to assess on the basis of a psychiatrist’s evaluation of
“whether the individual is mentally ill and . . . is in need of confined therapy.”103 Thus, the Court
is essentially applying “therapeutic jurisprudence” to “permit[] the state, in the name of therapy,
to deprive people of their liberty without the ‘great safeguards’ of the criminal law,” and relegating
mentally ill persons to a lesser personhood status in the legal system.104
D. Current Status of Mental Disability Law
i.

The Impact and Legacy of Sell

Coinciding with the rise in gene editing technology, has been relative silence on the part
of the Supreme Court to rule on issues that protect the bodily autonomy of the mentally ill. The
Court’s most recent case, Sell v. United States, was decided over 15 years ago, when CRISPR was
still in the earliest stages of its development as a gene editing tool.105 In Sell, the Court determined
that the constitutionality of involuntary administration of antipsychotics to render an individual
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competent to stand trial is based on a balancing test.106 This test considers (1) whether the
treatment is medically appropriate, (2) whether the treatment is substantially unlikely to have sideeffects that may undermine the trial’s fairness, and (3) whether, in the absence of less intrusive
alternatives, the treatment is necessary significantly to further important governmental, trialrelated interests.107 Though the Court attempted to narrow its holding only to the criminal
“competency to stand trial” context, the Sell test ultimately implies that a “dangerousness”
determination is not required to coerce an uncooperative mental patient to undergo treatment with
antipsychotic medication.108 Thus, the coercion determination is largely rooted in the assessment
and treatment decisions of medical personnel, rather than allowing the individual to maintain her
dignity in determining the medical treatment she wishes to receive.
Though Sell is a case based on criminal law, the standard it sets has broader implications
outside the criminal context.109 The distinction between civil and criminal law in the development
of mental health disability law has been significantly blurred, with varying standards being set in
each context.110 “Patent decisional inconsistency” can be seen in the way the Supreme Court’s
jurisprudence has developed with regard to the Constitutional rights of the mentally ill, and
“different substantive and procedural standards have been imposed in [a number of] cases”
involving the right to refuse medication.111 Furthermore, “the Court is equally comfortable with
pretextually characterizing what are clearly criminal penalties . . . as civil so as to save them from
constitutional challenge.”112

Thus, the implications of Sell may extend beyond the trial
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competency setting, rendering a patient’s ability to refuse medication virtually obsolete where a
medical necessity determination has been made.
IV.

Regulatory Control Over CRISPR Technology
Given that constitutional bodily autonomy protections are likely insufficient to protect from

inappropriate somatic uses of CRISPR in the psychiatric context, state and federal laws and
regulations will be relied on to prevent inappropriate use. While state law has the potential to
provide greater protection and can serve as a “gap filler” in the niche areas that issues such as
CRISPR create, state laws also lack uniformity and have a minimal influence on the scientific
community and biomedical industry as a whole.113 Thus, federal regulation must carry the brunt
of the responsibility in shaping and maintaining the legal landscape regarding gene therapy and
CRISPR technology.
A. Coordinated Framework
At present, federal regulation fails to sufficiently protect mentally ill patients from
improper applications of gene editing technologies such as CRISPR.114

The Coordinated

Framework for the Regulation of Biotechnology was first issued in 1986 by the White House
Office of Science and Technology Policy to clarify the roles of major administrative agencies in
regulating biotechnology products.115 While the Coordinated Framework provides “fundamental
federal guidance for regulating biotechnology products” and is intended to ensure oversight using
already established federal agencies,116 it is unclear whether these goals are being sufficiently
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achieved.117

“Despite recent efforts to update the Coordinated Framework, CRISPR-Cas9

technology and other gene-editing systems raise substantive questions about how (or whether) the
products resulting from these technologies are to be regulated, and if so, under what statutory
authorities.”118 This confusion has persisted since the 2017 update to the Coordinated Framework,
which explicitly left questions regarding genome editing and CRISPR technology to be decided
by future regulatory activities.119
As CRISPR is an emerging technology, the vast majority of its present use is in an
experimental context, leaving it outside of the FDA’s product safety regulatory authority. The
FDA “can impose requirements on research as a condition for receiving either federal funding or
FDA premarket review of a new medical product (such as a drug, device, or biologic);”120 however,
given that CRISPR is in a nascent stage, the FDA has yet to be faced with these challenges in any
substantially meaningful way. If the “federal tie” of government funding or premarket review is
absent, the FDA lacks jurisdiction over CRISPR research. As suggested earlier, this lack of
jurisdiction is not merely hypothetical, as researchers have shown willingness to seek private
sources of funding located outside the reach of federal regulation.
The FDA’s role in regulating CRISPR may remain complicated even within the product
safety context, as FDA regulation of a given product depends on whether it falls into one of the
specific categories over which the FDA has jurisdiction.121 The FDA has issued a short statement
regarding the self-administration of gene therapy, stating that “FDA considers any use of
CRISPR/Cas9 gene editing in humans to be gene therapy” regulated under the category of
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biologics.122 While courts generally defer to category determinations made by the FDA, deference
by the federal courts does not always occur.123 Furthermore, the FDA’s statement notes that “the
sale of these products is against the law.”124 Thus, in the absence of explicit statutory authority,
the door to legal arguments against FDA jurisdiction remains open to challenges based on both
statutory definitions and Commerce Clause limitations.125
Despite these challenges, the FDA has shown willingness to regulate gene therapies that it
does determine are within its jurisdiction, and it has recognized a need to keep FDA regulations
current with technological advances.126 For example, FDA guidance released in 1998 expanded
the regulatory requirements for clinical trials involving gene therapies so that greater emphasis
was placed on the disclosure of potential adverse events.127 In a moment where researchers appear
to be looking for regulatory guidance,128 the FDA should follow its own precedent. As it has done
with similarly controversial technologies, namely recombinant DNA technology, gene therapy and
cloning,129 the FDA must find a way to categorize the CRISPR so that it falls under FDA
jurisdiction. While such an assertion may not be failproof, it will provide the guidance the industry
is seeking and prevent the technology from falling into a regulatory tailspin.
B. 21st Century Cures Act
In December 2016, the federal regulatory restrictions on emerging technologies, including
CRISPR, were relaxed as a result of the enactment of the 21 Century Cures Act (hereinafter, Cures
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Act). “[D]esigned to help accelerate medical product development and bring new innovations and
advances to patients who need them faster and more efficiently,” the Cures Act seeks to reduce
bureaucratic impediments to clinical applications of precision medicine technologies.130 The
Cures Act includes a number of measures that, although oriented towards efficiency, will likely
have unintended safety consequences.
Sections 2011 through 2014 of the Cures Act are aimed at “Advancing Provision
Medicine” and amends the Public Health Service Act, which allows for FDA regulation of
biologics.131 The Cures Act provisions are largely focused on data analysis and patient privacy in
the context of biomedical research.132 While the Cures Act arguably creates greater protections
for patients’ information by requiring that a certificate of confidentiality is issued to research
participants,133 the Act’s overall emphasis on data sharing and interoperability generates concerns
regarding data management and abuse.134 Given that CRISPR applications would likely require
sequencing of a patient’s genome, research participating in Cures Act-related data sharing places
patients at risk of serious harm should genetic data be used inappropriately.135
In addition to Sections 2011 through 2014, Section 3023 of the Cures Act addresses the
protection of human research subjects. Section 3023 requires the Secretary of Health and Human
Services to harmonize human research regulations across federal agencies “[i]n order to simplify
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and facilitate compliance by researchers with applicable regulations.”136 The Cures Act further
requires that the harmonization “reduce regulatory duplication and unnecessary delays.”137 This
requirement resulted in the 2019 update to the Common Rule, discussed below.
C. Common Rule
The largely experimental nature of present CRISPR uses allows the Common Rule to play
a substantial role in regulating the technology’s use. The Common Rule (the Federal Policy for
the Protection of Human Subjects) was created in response to the Belmont Report, published in
1979,138 which outlined the main ethical principles to be safeguarded in conducting biomedical
and behavioral research with human participants.139 These main principles include (1) respect for
persons, (2) beneficence, and (3) justice, and they correlate to three practical measures that
researchers can take: informed consent, assessment of risk and potential benefits, and selection of
participants.140 The Belmont Report led to a revision of FDA regulations that “placed primary
emphasis on obtaining and documenting voluntary and informed consent, but provided little
guidance on assessment of risk and potential benefit or the selection of research participants.”141
In addition to the Belmont Report and the associated FDA revisions, the President’s Commission
for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research called for
standardization of research regulations across government agencies.142 Following this call, the
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Common Rule was created to codify the goals set forth by the Belmont Report and ensure their
application throughout the biomedical and behavioral research fields.143
The initial version of the Common Rule was created in 1981 and set out compliance
guidelines in accordance with the ethical principles of the Belmont Report;144 however, the Rule
suffers from limitations of its own. It is limited in its reach—the Common Rule applies only to
those studies that “(1) meet certain jurisdictional requirements[], (2) involve ‘research,’ and (3)
involve the use of ‘human subjects.’”145

As with FDA restrictions, the Common Rule

jurisdictional requirement involves a federal tie (e.g., federal funding) for the Rule to apply:146
“[i]f federal funds are not involved or if regulatory approval is not required, research activities
involving humans might not be subject to any form of oversight.”147 While it may be difficult to
imagine a large-scale study where a federal tie is not present, regulators should not discount private
actors. Since CRISPR technology is relatively affordable, it will be accessible to individuals
without the jurisdictional “hook”.148 For instance, an activist “biohacker” has already begun DIY
CRISPR experimentation on his own body while selling “kits” to online purchasers.149
The most recent update to the Common Rule was published in 2019150 and focuses on
requirements for informed consent. Since the Rule is intended to ensure “(1) respect for the
autonomous decision-making of those capable of providing it and (2) []protection for persons with
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diminished autonomy . . . the Common Rule seeks to ensure voluntary participation through
informed consent.”151 The 2019 revisions sought to redesign consent standards in an attempt to
streamline the informed consent process.152 As a result, the updated Common Rule requires that
informed consent procedures involve the application of a “‘reasonable person’ standard for
research disclosure, require[s] informed consent forms to begin with a ‘concise and focused
presentation’ of ‘key information,’ and authorize[s] individuals to provide ‘broad consent’ to
future research with identifiable data and biospecimens.”153 Whether these provisions will reduce
“administrative burden” while maintaining protections for human research subjects is debatable,
and the changes may open participants up to even greater vulnerability.154
In addition to the changes to informed consent protocols, the Revised Common Rule
contains definitional adjustments, including in its references to persons with mental impairments.
The term “mentally disabled persons” has been removed and replaced with “individuals with
impaired decision-making capacity.”155 Arguably, this change means that those diagnosed with
psychiatric disorders are no longer explicitly included as a “vulnerable population” under the
Rule.156 It is unclear what impact this will have on participants with mental illness involved in
psychiatric research.157 Notably, the Revised Common Rule fails to address Belmont Report goals
other than informed consent. Further guidance on selection of participants would have been
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particularly pertinent in the psychiatric research context, as these patients are particularly
vulnerable to coercion in the consent process.158
D. Other Sources of Guidance and Potential Solutions
While a thorough examination of the international debate on CRISPR research is outside
the scope of this article, the ideas arising out of that debate may provide important insights to
consider in the development of domestic CRISPR policy. Several international organizations have
begun working on CRISPR policy. For example, the World Health Organization has established
an advisory committee to examine genome editing issues, but the committee’s work is still
developing.159 In addition to the WHO Committee, the International Commission on Clinical Use
of Heritable Human Genome Editing is also developing guidance,160 and the UK Fertilization and
Embryology Authority, though dedicated to assisted reproductive technology, may be an important
resource regarding how to approach bioethics questions regarding genetics.161 Notably, however,
as in the United States, the primary concern of the international discussion has been germ-line
editing.162 Thus, the international community has largely ignored the use of genetic editing in
somatic cell lines, which would likely be a major component of psychiatric CRISPR
applications.163
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There is presently no binding international consensus on the use of CRISPR technology;164,
165

however, the creation of laws and policies at the national level can act as an important influence

in guiding corporate research and development decisions:
There are government guidelines in other areas as well. These provisions
technically are not enforceable, and yet they are very strongly persuasive because
complying with them creates what essentially is a safe haven for companies. They
know that if they stay within the guidelines, they are not going to run afoul of some
actual regulation or law. These guidelines also create strong social norms . . . from
which nations feel free to deviate only when they can provide justification that it is
necessary to achieve some public benefit.166
Government-created, binding guidelines are therefore essential.167 While ethical discussions
within the scientific community are important to foster debate and establish some social consensus,
these discussions, as evidenced by Professor He’s “CRISPR babies”, do little to ensure actual
adherence.168 Clear and straightforward regulation from domestic governments might create
sufficient industry pressure to keep rogue experiments like He’s from reoccurring.
In the United States, the requisite clarity would ideally come from Congress in the form of
a statute outlining strict limitations on both somatic and germline applications of CRISPR
technology; however, present legislative paralysis suggests that a federal statute is unlikely at any
point in the near future.169 In the meantime, the FDA should seek to provide greater informal
guidance to industry, outlining how CRISPR fits into the current regulatory scheme and
prohibiting its use on individuals under sixteen and other vulnerable populations. In addition, the
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FDA should require that clinical trials involving CRISPR employ a “Common Rule plus” approach
to informed consent, where researchers must show that they have outlined the potential risks
associated with CRISPR treatment and provided the patient with adequate time to consider his or
her options. Furthermore, as CRISPR is first and foremost a methodology, states should seek to
pass legislation or professional board guidance limiting somatic use of CRISPR to patients over
the age of sixteen, where strict informed consent procedures are followed, the treatment is
medically necessary, and alternative treatment options prove substantially deficient in managing
the patient’s illness.

Such state laws will allow for regulation of the practice of medical

applications of CRISPR, not just the sale of a product (which may not even be necessary to perform
CRISPR edits), and prevent a legal vacuum should federal law prove insufficient.
V.

Conclusion
Many of the more concerning applications of CRISPR technology are still far off in reality;

however, leaders should take this opportunity to get ahead of the science in a realm where policy
is often far outpaced by technology. As the psychiatric context makes clear, somatic applications
may be just as problematic as germ-line uses of CRISPR, and we must carefully consider the
consequences of engaging in biological manipulations that cut to the core of an individual’s
personhood. It is doubtful Constitutional protections will be sufficient once gene editing becomes
widespread, especially as applied to mentally ill persons who are civilly committed or otherwise
institutionalized. As used in the experimental context, clear regulatory guidance from the FDA,
NIH, and similar agencies would not only serve American researchers, but could help to shape
industry standards and encourage the development of international policies that carry more weight.
CRISPR must be taken seriously, even in its somatic applications, and the government should seek
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to develop ironclad protections that enable those patients desperate for novel treatments to receive
care without being unnecessarily placed at risk.
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